Neuphoria Therapeutics (NEUP) is scheduled to report Q3 earnings on May 23, 2026. Analysts estimate EPS of $-0.56 and quarterly revenue of N/A.

In the most recent quarter (Q2), Neuphoria Therapeutics reported EPS of $-0.77, missing estimates of $-0.56 by 0.38%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Neuphoria Therapeutics has missed EPS estimates in 3 consecutive quarters.

Over the last 4 quarters, Neuphoria Therapeutics has averaged an EPS surprise of 1.98% and a revenue surprise of 0.00%.